


Status: Currently Official on 17-Feb-2025
 Official Date: Official as of 01-Nov-2020
 Document Type: USP Monographs
 DocId: GUID-E40BE710-0550-4A91-9A6B-A8FF1DFB5B75_3_en-US
 DOI: https://doi.org/10.31003/USPNF_M88090_03_01
 DOI Ref: h39v5

© 2025 USPC
 Do not distribute

Verapamil Hydrochloride



$C_{27}H_{38}N_2O_4 \cdot HCl$ 491.06

Benzeneacetonitrile, α -[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]propyl]-3,4-dimethoxy- α -(1-methylethyl)-, monohydrochloride, ($\pm$); ($\pm$)-5-[[3,4-Dimethoxyphenethyl]methylamino]-2-(3,4-dimethoxyphenyl)-2-isopropylvaleronitrile monohydrochloride CAS RN[®]: 152-11-4; UNII: V3888OEY5R.

DEFINITION

Verapamil Hydrochloride contains NLT 98.0% and NMT 102.0% of Verapamil Hydrochloride ($C_{27}H_{38}N_2O_4 \cdot HCl$), calculated on the dried basis.

IDENTIFICATION

- **A. SPECTROSCOPIC IDENTIFICATION TESTS (197), Infrared Spectroscopy: 197K**
- **B.** The retention time of the major peak for verapamil in the *Sample solution* corresponds to that of *Standard solution B*, as obtained in the test for *Organic Impurities*.
- **C. IDENTIFICATION TESTS—GENERAL, Chloride (191):** Meets the requirements

ASSAY

PROCEDURE

Buffer: 1.23 g/L of sodium acetate containing about 33 mL/L of glacial acetic acid

Mobile phase: Acetonitrile, 2-aminoheptane, and *Buffer* (300:5:700)

Standard solution: 1 mg/mL of [USP Verapamil Hydrochloride RS](#) in *Mobile phase*

Sample solution: 1 mg/mL of Verapamil Hydrochloride in *Mobile phase*

Chromatographic system

(See [Chromatography \(621\), System Suitability](#).)

Mode: LC

Detector: UV 278 nm

Column: 4.6-mm $\times$ 15-cm; 5- μ m packing L1

Flow rate: 0.9 mL/min

Injection volume: 10 μ L

Run time: NLT 2 times the retention time of verapamil

System suitability

Sample: *Standard solution*

Suitability requirements

Tailing factor: NMT 2.0

Relative standard deviation: NMT 0.73%

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of verapamil hydrochloride ($C_{27}H_{38}N_2O_4 \cdot HCl$) in the portion of Verapamil Hydrochloride taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

r_U = peak response of verapamil from the *Sample solution*

r_s = peak response of verapamil from the *Standard solution*

C_s = concentration of [USP Verapamil Hydrochloride RS](#) in the *Standard solution* (mg/mL)

C_u = concentration of Verapamil Hydrochloride in the *Sample solution* (mg/mL)

Acceptance criteria: 98.0%–102.0% on the dried basis

IMPURITIES

- [RESIDUE ON IGNITION \(281\)](#): NMT 0.1%

Change to read:

- **ORGANIC IMPURITIES**

Buffer ▲ and Mobile phase: Prepare ▲ (ERR 1-Nov-2020) as directed in the Assay.

System suitability solution: 1.9 mg/mL of [USP Verapamil Hydrochloride RS](#) and 1.5 mg/mL of [USP Verapamil Related Compound B RS](#) in *Mobile phase*

Standard solution A: 5.6 µg/mL of [USP Verapamil Hydrochloride RS](#) in *Mobile phase*

Standard solution B: 9.4 µg/mL of [USP Verapamil Hydrochloride RS](#) in *Mobile phase*

Sample solution: 1.9 mg/mL of Verapamil Hydrochloride in *Mobile phase*

Chromatographic system

(See [Chromatography \(621\)](#), [System Suitability](#).)

Mode: LC

Detector: UV 278 nm

Column: 4.6-mm × 12.5- to 15-cm; packing L1

Flow rate: 0.9 mL/min

Injection volume: 10 µL

Run time: NLT 4 times the retention time of verapamil

System suitability

Sample: *System suitability solution*

[NOTE—The relative retention times for verapamil related compound B and verapamil are 0.88 and 1.0, respectively.]

Suitability requirements

Resolution: NLT 1.5 between the verapamil related compound B and verapamil peaks

Relative standard deviation: NMT 2.0%

Analysis

Samples: *Sample solution*, *Standard solution A*, and *Standard solution B*

Acceptance criteria

Individual impurities: Any single peak response is not greater than that of the verapamil peak response from *Standard solution A* (0.3%).

Total impurities: The sum of the peak responses, other than that of verapamil, from the *Sample solution* is not greater than the verapamil peak response from *Standard solution B* (0.5%).

SPECIFIC TESTS

- [pH \(791\)](#)

Sample solution: 50 mg/mL. Prepare with gentle heating.

Acceptance criteria: 4.5–6.5

- [Loss on Drying \(731\)](#)

Analysis: Dry at 105° for 2 h.

Acceptance criteria: NMT 0.5%

ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE:** Preserve in tight, light-resistant containers. Store at controlled room temperature.

- [USP REFERENCE STANDARDS \(11\)](#)

[USP Verapamil Hydrochloride RS](#)

[USP Verapamil Related Compound B RS](#)

Benzeneacetonitrile, α-[2-[[2-(3,4-dimethoxyphenyl)-ethyl]methylamino]ethyl]-3,4-dimethoxy-α-(1-methylethyl)-, monohydrochloride.

$C_{26}H_{36}N_2O_4 \cdot HCl$

477.05